Safety and Efficacy of Felid Herpesvirus-1 Deletion Mutants in Cats
| Autor: | Kim S. Giessler, Roger K. Maes, John M. Kruger, Yao Lee, Gisela Soboll Hussey, Matti Kiupel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine 040301 veterinary sciences lcsh:QR1-502 Immunization Secondary Antibodies Viral Cat Diseases Virus Replication lcsh:Microbiology Article Virus Cell Line 0403 veterinary science 03 medical and health sciences Viral Envelope Proteins Virology Animals Medicine Varicellovirus Pathogen CATS Virulence biology business.industry Immunogenicity thymidine kinase (TK) cats Viral Vaccines Herpesviridae Infections 04 agricultural and veterinary sciences vaccination Antibodies Neutralizing Immunity Innate Virus Shedding Vaccination Interleukin 10 030104 developmental biology Infectious Diseases glycoprotein E (gE) Immunization biology.protein Cytokines Antibody business Felid herpesvirus-1 serine/threonine protein kinase (PK) Gene Deletion |
| Zdroj: | Viruses Volume 13 Issue 2 Viruses, Vol 13, Iss 163, p 163 (2021) |
| ISSN: | 1999-4915 |
| DOI: | 10.3390/v13020163 |
| Popis: | Felid herpesvirus-1 (FeHV-1) is an important respiratory and ocular pathogen of cats and current vaccines are limited in duration and efficacy because they do not prevent infection, viral nasal shedding and latency. To address these shortcomings, we have constructed FeHV-1 gE-TK- and FeHV-1 PK- deletion mutants (gE-TK- and PK-) using bacterial artificial chromosome (BAC) mutagenesis and shown safety and immunogenicity in vitro. Here, we compare the safety and efficacy of a prime boost FeHV-1 gE-TK- and FeHV-1 PK- vaccination regimen with commercial vaccination in cats. Cats in the vaccination groups were vaccinated at 3-week intervals and all cats were challenge infected 3 weeks after the last vaccination. Evaluations included clinical signs, nasal shedding, virus neutralizing antibodies (VN), cytokine mRNA gene expression, post-mortem histology and detection of latency establishment. Vaccination with gE-TK- and PK- mutants was safe and resulted in significantly reduced clinical disease scores, pathological changes, viral nasal shedding, and viral DNA in the trigeminal ganglia (the site of latency) following infection. Both mutants induced VN antibodies and interferons after immunization. In addition, after challenge infection, we observed a reduction of IL-1&beta expression, and modulation of TNF&alpha TGF&beta and IL10 expression. In conclusion, this study shows the merits of using FeHV-1 deletion mutants for prevention of FeHV-1 infection in cats. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |